ClinicalTrials.gg
WithdrawnNCT07492875Updated May 8, 2026

Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia

A Phase 3 interventional study of Nogapendekin alfa inbakicept (NAI) and agenT-797 in Community-Acquired Pneumonia (CAP), Acute Respiratory Distress Syndrome (ARDS) and Sepsis, sponsored by ImmunityBio, Inc.. Withdrawn. Open to participants aged 18 Years to 105 Years. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by ImmunityBio, Inc. · Phase 3, Interventional, and Treatment

Why this study was withdrawn
New protocol developed

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 105 Years
Sex
All
01

Study summary

This is a Phase 3, randomized, blinded, and placebo-controlled clinical trial investigating a new combination treatment for critically ill adults who have severe community-acquired pneumonia, especially if they also have sepsis or acute respiratory distress syndrome.

The study aims to determine if adding the experimental agents, Nogapendekin Alfa Inbakicept and iNKT cells, to standard medical care can reduce the 28-day all-cause mortality rate compared to standard care alone with a placebo.

Read the detailed description

This multi-center, randomized, blinded, and placebo-controlled Phase 3 study aims to address the high mortality and complication rates associated with severe community-acquired pneumonia (CAP) in critically ill adults, particularly those experiencing immune deficiency like lymphopenia or immunoparalysis.

Current standard treatments for severe CAP focus on infection control and organ support but often do not directly restore the patient's compromised immune function. This trial investigates a novel immunotherapeutic approach using a combination of two agents:

  1. Nogapendekin Alfa Inbakicept (NAI): An IL-15 receptor agonist designed to activate natural killer (NK) and CD8+ T-cells, aiming to enhance the body's immune competence.
  2. iNKT Cells (invariant natural killer T cells): An allogeneic cell therapy intended to rapidly orchestrate both innate and adaptive immune responses.

The central hypothesis is that this combination therapy, when added to standard of care treatments, can reverse immune dysfunction, clear infections, regulate inflammation, and ultimately improve survival and reduce severe complications such as secondary infections and prolonged organ support requirements in this vulnerable patient population. The study will meticulously assess the safety and efficacy of this combined approach, building on promising signals from earlier research.

02

Conditions studied

  • Community-Acquired Pneumonia (CAP)
  • Acute Respiratory Distress Syndrome (ARDS)
  • Sepsis
  • Lymphopenia
  • Immunoparalysis

Keywords

  • Community-Acquired Pneumonia
  • Severe CAP
  • Sepsis
  • Acute Respiratory Distress Syndrome (ARDS)
  • Nogapendekin Alfa Inbakicept (NAI)
  • ANKTIVA
  • iNKT Cells
  • Invariant Natural Killer T cells (AgenT-797)
  • Immunotherapy
  • Immunomodulation
  • Lymphopenia
  • Critical Illness
  • Randomized Controlled Trial
  • Phase 3
03

In context

Community-Acquired Pneumonia

325 studies on the registry are indexed under Community-Acquired Pneumonia; 78 are open to participants now.

Browse Community-Acquired Pneumonia studies →

Lead sponsor

ImmunityBio, Inc. is the lead sponsor of 83 studies on the registry; 14 are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 17 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 105 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years, adult participants of any gender.
  2. Critically ill adults requiring admission to an ICU-unit due to severe community acquired pneumonia.

    • Severe CAP is defined by the presence of one major criterion or at least three minor criteria:
    • Major Criteria (any one = severe CAP):
    • Respiratory failure requiring mechanical ventilation
    • Septic shock requiring vasopressors to maintain blood pressure
    • Minor Criteria (≥3 indicates severe CAP):
    • Tachypnea: Respiratory rate ≥ 30 breaths/min
    • Hypoxemia: PaO2/FiO2 ratio ≤ 200
    • Multilobar infiltrates on chest imaging
    • Confusion or disorientation (new onset mental status changes)
    • Uremia: Blood urea nitrogen (BUN) ≥ 20 mg/dL (7.1 mmol/L)
    • Thrombocytopenia: count \< 100,000/μL
    • Hypothermia: Core temperature \< 36.0 °C (96.8 °F)
    • Hypotension requiring aggressive fluid resuscitation
  3. Hospital admission with a diagnosis of CAP within 72 hours.
  4. Lymphopenia/ Absolute Lymphocyte Count (ALC): ALC \< 1,500/μL (not secondary due to chemotherapy).
  5. Participants already treated by antibiotics (at least one dose since admission to the ICU).
  6. : Ability to obtain informed consent from participant or legally authorized representative (given the incapacity of many ICU participants, consent via surrogate/Legally Authorized Representative is allowed per ethics approval).

Exclusion criteria

Exclusion Criteria:

  1. Hematologic (eg, active leukemia and lymphoma, not in remission).
  2. Post CAR-T cells therapy or hematopoietic cell transplant for ALL, NHL or Multiple Myeloma less than 3 months prior to enrollment.
  3. Participant diagnosed with cytokine release syndrome.
  4. Participant receiving colony stimulating factors eg, G-CSF.
  5. Clinical history or radiological imaging suggesting aspiration of gastric content.
  6. Participant with advanced dementia or prolonged bedridden status.
  7. Pregnancy or breastfeeding.
  8. High-dose therapy at baseline: eg, > 0.5 mg/kg prednisone (or equivalent). Note: Use of low-dose for septic shock or ARDS (eg, dexamethasone 6 mg/day for ARDS) is not an exclusion, as it is standard care such use will be recorded and balanced between arms.
  9. Uncontrolled or inflammatory disease requiring immunosuppressive therapies (to avoid confounding immune effects or exacerbation).
  10. \< 24-48 hours or moribund condition despite care (Investigator judgment that participant will not survive long enough to benefit or be evaluated).
  11. Active uncontrolled bleeding or intracerebral hemorrhage (cell therapy infusion could transiently affect hemodynamics or coagulation; exclude if such conditions make the intervention risk unjustifiable).
  12. Known to ingredients used in cell product formulation such as DMSO.
  13. Treated by antibiotics for a respiratory infection for more than seven days at the time of hospitalization (except if culture and sensitivities determine a resistant organism to the administered antibiotics).
  14. Known active Viral Hepatitis A, B, or C.
  15. History of (HIV) with current \< 350 cells/µL and/or a detectable HIV viral load.
  16. The Investigator believes that participating in the trial is not in the best interest of the participant, or the Investigator considers the participant unsuitable for enrollment (such as due to unpredictable risks or severe co-morbidities).
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Experimental Arm

    Participants in this arm receive the investigational treatments: Nogapendekin Alfa Inbakicept (NAI) administered subcutaneously on Day 1 and Day 10, and iNKT cells administered intravenously on Day 3. All participants also receive standard of care (SOC) treatments for severe community-acquired pneumonia, with or without sepsis/ARDS.

    Biological: Nogapendekin alfa inbakicept (NAI)

  • Placebo comparator
    Control Arm

    Participants in this arm receive placebos matching the investigational treatments: a subcutaneous placebo on Day 1 and Day 10, and an intravenous placebo on Day 3. All participants also receive standard of care (SOC) treatments for severe community-acquired pneumonia, with or without sepsis/ARDS.

    Biological: agenT-797

Interventions

  • NAI is a soluble complex consisting of two protein subunits of a human IL-15 variant (nogapendekin alfa) bound with high affinity to a dimeric human IL 15Rα sushi domain/human IgG1 Fc fusion protein (inbakicept).

  • BiologicalagenT-797

    Allogeneic invariant NKT (iNKT) cell therapy - an off-the-shelf cell therapy that can rapidly orchestrate both innate and adaptive immunity.

06

What researchers measure

Primary outcomes

  1. 28-day all-cause mortality

    Up to Day 28 from randomization. (Participants lost to follow-up before Day 28 will be censored at their last known date alive; participants alive on Day 28 will be censored at Day 28).

    Time frame: 30 days after the last dose of study drug

Secondary outcomes

  1. ALC count

    Absolute Lymphocyte Count

    Time frame: From randomization through 28 days following randomization.

  2. Ventilator-Free days (VFD) through Day 28.

    The number of days a participant is free from mechanical ventilation.

    Time frame: Through 28 days following randomization.

  3. Number of ICU free days through Day 28.

    The number of days a participant is free from being in the Intensive Care Unit.

    Time frame: Through 28 days following randomization.

  4. Number of antibiotic free days through Day 28.

    The number of days a participant is free from antibiotic treatment.

    Time frame: Through 28 days following randomization.

  5. Number of days alive and free of organ support through 28 days.

    The number of days a participant is alive and does not require organ support.

    Time frame: Through 28 days following randomization.

  6. Time from first administration of study drug to ICU discharge.

    The duration from the first dose of study drug until the participant is discharged from the Intensive Care Unit.

    Time frame: From first study drug administration until ICU discharge, assessed up to 90 days; ICU discharge date documented from medical record (participants not discharged by Day 90 censored at Day 90; deaths prior to discharge counted as competing events).

  7. Time from first administration of study drug to hospital discharge.

    The duration from the first dose of study drug until the participant is discharged from the hospital.

    Time frame: From first study drug administration until hospital discharge, assessed up to 90 days; hospital discharge date documented from medical record (participants not discharged by Day 90 censored at Day 90; deaths prior to discharge counted as competing events

  8. Incidence of secondary infections through Day 28 and for the entire study.

    The occurrence rate of infections that develop after the start of study treatment.

    Time frame: From randomization through 90 days following randomization.

  9. 90-day all-cause mortality.

    Death from any cause.

    Time frame: Through 90 days following randomization.

Other outcomes

  1. Treatment Emergent Adverse Events (TEAEs).

    Any adverse event that occurred or worsened after the start of study treatment.

    Time frame: From first study drug administration through 30 days after the last study drug administration.

  2. Serious Adverse Events (SAEs).

    Any adverse event that meets predefined serious criteria (e.g., fatal, life-threatening, requires hospitalization).

    Time frame: From first study drug administration through 30 days after the last study drug administration, with related SAEs followed until resolution or stabilization.

  3. Grade ≥3 TEAEs

    Treatment emergent adverse events with a severity grade of 3 or higher, based on CTCAE Version 6.0 (or specified grading for CRS/ICANS).

    Time frame: From first study drug administration through 30 days after the last study drug administration.

  4. Safety laboratory tests

    Results from various clinical laboratory assessments

    Time frame: At screening, before first study drug administration, on Day 1, 3, 5, 7, 10, then every 3 days until end of ICU stay, at end of ICU stay, and at 28-day follow-up.

  5. Heart rate

    Resting heart rate measured by bedside monitor or manual pulse; recorded as the value closest to the scheduled assessment time (beats per minute, bpm).

    Time frame: At screening; pre-dose and 30 min post-dose on Days 1, 3, and 10; daily during hospitalization (up to 10 days); every 4 h for 24 h after Day 3 iNKT infusion; at ICU discharge; and at Day 28 and Day 90 follow-up.

  6. Systolic and diastolic blood pressure

    Noninvasive cuff blood pressure or arterial line value if present; record systolic/diastolic (mmHg) nearest scheduled assessment.

    Time frame: At screening; pre-dose and 30 min post-dose on Days 1, 3, and 10; daily during hospitalization (up to 10 days); every 4 h for 24 h after Day 3 iNKT infusion; at ICU discharge; and at Day 28 and Day 90 follow-up.

  7. Respiratory rate

    Respiratory rate measured by bedside monitor or counted manually over 60 seconds; record breaths per minute nearest scheduled assessment.

    Time frame: At screening; pre-dose and 30 min post-dose on Days 1, 3, and 10; daily during hospitalization (up to 10 days); every 4 h for 24 h after Day 3 iNKT infusion; at ICU discharge; and at Day 28 and Day 90 follow-up.

  8. Oxygen saturation (SpO2)

    Peripheral oxygen saturation by pulse oximetry (%) on current supplemental oxygen; record SpO2 and concurrent FiO2/oxygen delivery method.

    Time frame: At screening; pre-dose and 30 min post-dose on Days 1, 3, and 10; daily during hospitalization (up to 10 days); every 4 h for 24 h after Day 3 iNKT infusion; at ICU discharge; and at Day 28 and Day 90 follow-up.

  9. Body temperature

    Core or oral temperature measured per site standard (use same method consistently for a participant); record value in degrees Celsius (°C) nearest scheduled assessment.

    Time frame: At screening; pre-dose and 30 min post-dose on Days 1, 3, and 10; daily during hospitalization (up to 10 days); every 4 h for 24 h after Day 3 iNKT infusion; at ICU discharge; and at Day 28 and Day 90 follow-up.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2026; primary completion for Apr 2029, 36 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2025
First posted
Mar 25, 2026
StartEst.
Apr 15, 2026
Primary completionEst.
Apr 15, 2029
CompletionEst.
Dec 31, 2029
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07492875
Lead sponsor
ImmunityBio, Inc.
Responsible party
Sponsor
First posted
Mar 25, 2026
Start date
Apr 15, 2026 (estimated)
Primary completion
Apr 15, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
May 8, 2026

Study contacts

Jayson Garmizo
study director · ImmunityBio, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nogapendekin alfa inbakicept

Start the discussion